The estimated Net Worth of Lisa M. Giles is at least $286 Thousand dollars as of 12 August 2016. Ms. Giles owns over 823 units of GenMark Diagnostics Inc stock worth over $127,965 and over the last 10 years she sold GNMK stock worth over $0. In addition, she makes $157,855 as Independent Director at GenMark Diagnostics Inc.
Sign up
Ms. Giles GNMK stock SEC Form 4 insiders trading
Lisa has made over 2 trades of the GenMark Diagnostics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently she bought 823 units of GNMK stock worth $7,736 on 12 August 2016.
The largest trade she's ever made was buying 4,000 units of GenMark Diagnostics Inc stock on 3 November 2015 worth over $26,400. On average, Lisa trades about 268 units every 16 days since 2015. As of 12 August 2016 she still owns at least 5,323 units of GenMark Diagnostics Inc stock.
You can see the complete history of Ms. Giles stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Lisa Giles biography
Lisa M. Giles serves as Independent Director of the Company. Since 2000, Ms. Giles has served as CEO and President of Giles & Associates Consultancy, Inc., a strategy consulting firm serving life science and healthcare industry clients, which she formed in 2000. In 2012, Ms. Giles also founded and currently serves as the CEO of Optivara, Inc., a business process as a service (BPAS) company also serving the life sciences industry. Prior to 2000, Ms. Giles served as Vice President of Strategy and Development for G.D. Searle & Company, where she oversaw global pharmaceutical strategic planning, portfolio decision analysis, portfolio optimization and transaction analysis. Ms. Giles previously served as a member of the board of directors of Durata Therapeutics, Inc., from August 2012 until its acquisition by Actavis plc in November 2014. Ms. Giles is a trustee on the board of Northwestern Memorial Hospital Foundation and serves as a member of the NMHC Quality Committee. Ms. Giles holds a B.S. from Juniata College and completed the executive management program at Stanford University and The University of Chicago. In 2015, Ms. Giles was recognized by PharmaVoice as one of the “Top 100 Most Influential People in Life Sciences.”
What is the salary of Lisa Giles?
As the Independent Director of GenMark Diagnostics Inc, the total compensation of Lisa Giles at GenMark Diagnostics Inc is $157,855. There are 6 executives at GenMark Diagnostics Inc getting paid more, with Scott Mendel having the highest compensation of $1,749,300.
How old is Lisa Giles?
Lisa Giles is 61, she's been the Independent Director of GenMark Diagnostics Inc since 2015. There are 3 older and 6 younger executives at GenMark Diagnostics Inc. The oldest executive at GenMark Diagnostics Inc is Daryl Faulkner, 71, who is the Independent Director.
What's Lisa Giles's mailing address?
Lisa's mailing address filed with the SEC is C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL, A8, H4M 2X6.
Insiders trading at GenMark Diagnostics Inc
Over the last 14 years, insiders at GenMark Diagnostics Inc have traded over $27,572,889 worth of GenMark Diagnostics Inc stock and bought 454,838 units worth $2,182,328 . The most active insiders traders include Hany Massarany, Jon Faiz Kayyem, and Kevin C Oboyle. On average, GenMark Diagnostics Inc executives and independent directors trade stock every 5 days with the average trade being worth of $141,403. The most recent stock trade was executed by Michael Gleeson on 14 April 2021, trading 27,667 units of GNMK stock currently worth $326,471.
What does GenMark Diagnostics Inc's logo look like?
Complete history of Ms. Giles stock trades at GenMark Diagnostics Inc and Milestone Pharmaceuticals Inc
GenMark Diagnostics Inc executives and stock owners
GenMark Diagnostics Inc executives and other stock owners filed with the SEC include:
-
Scott Mendel,
President, Chief Executive Officer, Director -
Johnny Ek,
Chief Financial Officer -
Michael Gleeson,
Senior Vice President, Corporate Accounts -
Eric Stier,
Senior Vice President, General Counsel, Secretary -
James Fox,
Non-Executive Independent Director -
Kevin O'Boyle,
Independent Chairman of the Board -
Lisa Giles,
Independent Director -
Daryl Faulkner,
Independent Director -
Michael Kagnoff,
Independent Director -
Tyler Jensen,
Senior Vice President - Engineering and Product Technical Support -
Jon Faiz Kayyem,
President & CEO -
Jennifer Anne Williams,
SVP Global Operations -
Wade R. Stevenson,
SVP, North America Sales -
Brian Andrew Mitchell,
SVP, Operations -
Christine Shaw,
VP, Assay Development -
John Frederick Ek,
Chief Financial Officer -
Richard B Slansky,
Chief Financial Officer -
Stephen T Worland,
Director -
Jeffrey Alan Hawkins,
SVP, Marketing & Bus Dev -
Ingo Chakravarty,
SVP, International -
Christopher M Gleeson,
Director -
James B. Mc Nally,
SVP, Marketing and Bus. Dev. -
Jorge Garces,
SVP, Research & Development -
Paul Ross,
CFO & Secretary -
Pankaj Singhal,
Sr. VP, Product Dev & Mftg -
Matthew Robert Cohen,
SVP, Gen Counsel & Secretary -
John Bellano,
SR. VP, Commercial Operations -
Steven J Kemper,
CFO, Treasurer & Secretary -
Bradley Calvin,
Senior VP, Global Marketing -
Scott Alexander O'brien,
SVP, Global Mktg & Int'l Sales -
Hany Massarany,
President and CEO -
Sarah Hollis Winkler,
VP, Human Resources -
Alan Baer Maderazo,
VP, Qual, Reg, & Clin Affairs -
Michael John Harkins,
SVP, Sales -
Abdul Chohan,
SVP Operations